Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T83145
(Former ID: TTDC00046)
|
|||||
Target Name |
Nuclear factor NF-kappa-B (NFKB)
|
|||||
Synonyms |
Nuclear factor of kappa light polypeptide gene enhancer in B-cells; DNA-binding factor KBF
Click to Show/Hide
|
|||||
Gene Name |
NFKB1; NFKB2; RELA; RELB; REL
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 2 Target-related Diseases | + | ||||
1 | Irritable bowel syndrome [ICD-11: DD91] | |||||
2 | Rheumatoid arthritis [ICD-11: FA20] | |||||
Function |
NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis.
Click to Show/Hide
|
|||||
UniProt ID | ||||||
Sequence |
MAEDDPYLGRPEQMFHLDPSLTHTIFNPEVFQPQMALPTDGPYLQILEQPKQRGFRFRYV
CEGPSHGGLPGASSEKNKKSYPQVKICNYVGPAKVIVQLVTNGKNIHLHAHSLVGKHCED GICTVTAGPKDMVVGFANLGILHVTKKKVFETLEARMTEACIRGYNPGLLVHPDLAYLQA EGGGDRQLGDREKELIRQAALQQTKEMDLSVVRLMFTAFLPDSTGSFTRRLEPVVSDAIY DSKAPNASNLKIVRMDRTAGCVTGGEEIYLLCDKVQKDDIQIRFYEEEENGGVWEGFGDF SPTDVHRQFAIVFKTPKYKDINITKPASVFVQLRRKSDLETSEPKPFLYYPEIKDKEEVQ RKRQKLMPNFSDSFGGGSGAGAGGGGMFGSGGGGGGTGSTGPGYSFPHYGFPTYGGITFH PGTTKSNAGMKHGTMDTESKKDPEGCDKSDDKNTVNLFGKVIETTEQDQEPSEATVGNGE VTLTYATGTKEESAGVQDNLFLEKAMQLAKRHANALFDYAVTGDVKMLLAVQRHLTAVQD ENGDSVLHLAIIHLHSQLVRDLLEVTSGLISDDIINMRNDLYQTPLHLAVITKQEDVVED LLRAGADLSLLDRLGNSVLHLAAKEGHDKVLSILLKHKKAALLLDHPNGDGLNAIHLAMM SNSLPCLLLLVAAGADVNAQEQKSGRTALHLAVEHDNISLAGCLLLEGDAHVDSTTYDGT TPLHIAAGRGSTRLAALLKAAGADPLVENFEPLYDLDDSWENAGEDEGVVPGTTPLDMAT SWQVFDILNGKPYEPEFTSDDLLAQGDMKQLAEDVKLQLYKLLEIPDPDKNWATLAQKLG LGILNNAFRLSPAPSKTLMDNYEVSGGTVRELVEALRQMGYTEAIEVIQAASSPVKTTSQ AHSLPLSPASTRQQIDELRDSDSVCDSGVETSFRKLSFTESLTSGASLLTLNKMPHDYGQ EGPLEGKI Click to Show/Hide
|
|||||
HIT2.0 ID | T44LWL |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
1 | Sulfasalazine | Drug Info | Approved | Rheumatoid arthritis | [1], [2] | |
Clinical Trial Drug(s) | [+] 12 Clinical Trial Drugs | + | ||||
1 | Edasalonexent | Drug Info | Phase 3 | Duchenne dystrophy | [3] | |
2 | Laquinimod | Drug Info | Phase 3 | Lupus | [4], [5] | |
3 | MD1003 | Drug Info | Phase 3 | Multiple sclerosis | [6] | |
4 | Triptolide | Drug Info | Phase 3 | Autoimmune diabetes | [7] | |
5 | CAT 1004 | Drug Info | Phase 2 | Duchenne dystrophy | [8] | |
6 | CZEN-002 | Drug Info | Phase 2 | Fungal infection | [9] | |
7 | L-ornithine phenylacetate | Drug Info | Phase 2 | Acute liver failure | [10] | |
8 | PRO22 | Drug Info | Phase 2 | Atopic dermatitis | [11] | |
9 | Recoflavone | Drug Info | Phase 2 | Inflammatory bowel disease | [12] | |
10 | Vadimezan | Drug Info | Phase 2 | Solid tumour/cancer | [13] | |
11 | XP-23829 | Drug Info | Phase 2 | Multiple sclerosis | [14] | |
12 | Avrina | Drug Info | Phase 1/2 | Skin infection | [15] | |
Patented Agent(s) | [+] 16 Patented Agents | + | ||||
1 | 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1 | Drug Info | Patented | Skin disease | [17] | |
2 | 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 2 | Drug Info | Patented | Skin disease | [17] | |
3 | 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3 | Drug Info | Patented | Skin disease | [17] | |
4 | 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4 | Drug Info | Patented | Skin disease | [17] | |
5 | PMID25553724-Compound-US2011000295210 | Drug Info | Patented | Immune System disease | [17] | |
6 | PMID25553724-Compound-US2011796857710 | Drug Info | Patented | Immune System disease | [17] | |
7 | PMID25553724-Compound-US2011799419010 | Drug Info | Patented | Immune System disease | [17] | |
8 | PMID25553724-Compound-US2011801300410 | Drug Info | Patented | Immune System disease | [17] | |
9 | PMID25553724-Compound-US2011803494010 | Drug Info | Patented | Immune System disease | [17] | |
10 | PMID25553724-Compound-US2011806744710 | Drug Info | Patented | Immune System disease | [17] | |
11 | PMID25553724-Compound-US2012810604610 | Drug Info | Patented | Immune System disease | [17] | |
12 | PMID25553724-Compound-US2012819831110 | Drug Info | Patented | Immune System disease | [17] | |
13 | PMID25553724-Compound-US2012820715110 | Drug Info | Patented | Immune System disease | [17] | |
14 | PMID25553724-Compound-US2012830453910 | Drug Info | Patented | Immune System disease | [17] | |
15 | PMID25553724-Compound-US2012832440110 | Drug Info | Patented | Immune System disease | [17] | |
16 | Tihotungstate derivative 1 | Drug Info | Patented | Nervous system disease | [17] | |
Discontinued Drug(s) | [+] 4 Discontinued Drugs | + | ||||
1 | P-1 | Drug Info | Discontinued in Phase 3 | Atopic dermatitis | [18] | |
2 | AS602868 | Drug Info | Discontinued in Phase 1 | Multiple myeloma | [20] | |
3 | MOL-218 | Drug Info | Terminated | Asthma | [21] | |
4 | Tyloxapol | Drug Info | Terminated | Cystic fibrosis | [22] | |
Mode of Action | [+] 3 Modes of Action | + | ||||
Activator | [+] 2 Activator drugs | + | ||||
1 | Sulfasalazine | Drug Info | [1] | |||
2 | PS-1145 | Drug Info | [31] | |||
Inhibitor | [+] 84 Inhibitor drugs | + | ||||
1 | Edasalonexent | Drug Info | [6] | |||
2 | MD1003 | Drug Info | [6] | |||
3 | Triptolide | Drug Info | [24] | |||
4 | CAT 1004 | Drug Info | [8] | |||
5 | Parthenolide | Drug Info | [27] | |||
6 | PRO22 | Drug Info | [11] | |||
7 | XP-23829 | Drug Info | [29] | |||
8 | 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1 | Drug Info | [17] | |||
9 | 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 2 | Drug Info | [17] | |||
10 | 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3 | Drug Info | [17] | |||
11 | 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4 | Drug Info | [17] | |||
12 | N-quinolin-benzene sulphonamide derivative 1 | Drug Info | [17] | |||
13 | N-quinolin-benzene sulphonamide derivative 3 | Drug Info | [17] | |||
14 | Olenolic acid acetate derivative 1 | Drug Info | [17] | |||
15 | PMID25553724-Compound-EP20132578214 2 | Drug Info | [17] | |||
16 | PMID25553724-Compound-US2011000295210 | Drug Info | [17] | |||
17 | PMID25553724-Compound-US2011796857710 | Drug Info | [17] | |||
18 | PMID25553724-Compound-US2011799419010 | Drug Info | [17] | |||
19 | PMID25553724-Compound-US2011801300410 | Drug Info | [17] | |||
20 | PMID25553724-Compound-US2011803494010 | Drug Info | [17] | |||
21 | PMID25553724-Compound-US2011806744710 | Drug Info | [17] | |||
22 | PMID25553724-Compound-US2012810604610 | Drug Info | [17] | |||
23 | PMID25553724-Compound-US2012819831110 | Drug Info | [17] | |||
24 | PMID25553724-Compound-US2012820715110 | Drug Info | [17] | |||
25 | PMID25553724-Compound-US2012830453910 | Drug Info | [17] | |||
26 | PMID25553724-Compound-US2012832440110 | Drug Info | [17] | |||
27 | PMID25553724-Compound-US20130116324 2 | Drug Info | [17] | |||
28 | PMID25553724-Compound-US20138552206 4 | Drug Info | [17] | |||
29 | PMID25553724-Compound-US20138552206 5 | Drug Info | [17] | |||
30 | PMID25553724-Compound-WO2011152671 2 | Drug Info | [17] | |||
31 | Quinoxaline derivative 1 | Drug Info | [17] | |||
32 | Quinoxaline derivative 2 | Drug Info | [17] | |||
33 | Quinoxaline derivative 3 | Drug Info | [17] | |||
34 | Quinoxaline derivative 5 | Drug Info | [17] | |||
35 | Quinoxaline derivative 6 | Drug Info | [17] | |||
36 | Tihotungstate derivative 1 | Drug Info | [17] | |||
37 | Tihourea derivative 1 | Drug Info | [17] | |||
38 | AS602868 | Drug Info | [31] | |||
39 | Gliotoxin | Drug Info | [32] | |||
40 | HELENALIN | Drug Info | [33] | |||
41 | MOL-218 | Drug Info | [34] | |||
42 | Tyloxapol | Drug Info | [35], [36] | |||
43 | 15-ACETOXY-EREMANTHOLIDE B | Drug Info | [33] | |||
44 | 15-DEOXYBUDLEIN A | Drug Info | [33] | |||
45 | 15-isobutyrylmiguanin | Drug Info | [37] | |||
46 | 1beta-methoxy-miller-9Z-enolide | Drug Info | [37] | |||
47 | 2-amino-N-(quinolin-8-yl)benzenesulfonamide | Drug Info | [38] | |||
48 | 2-oxoguaia-1,4,11(13)-trien-12,8alpha-olide | Drug Info | [37] | |||
49 | 2beta-methoxy-2-deethoxyphantomolin | Drug Info | [37] | |||
50 | 3,4-epoxydehydroleucodin | Drug Info | [37] | |||
51 | 4,5-ISOBUDLEIN A | Drug Info | [37] | |||
52 | 4-nitro-N-(quinolin-8-yl)benzenesulfonamide | Drug Info | [38] | |||
53 | 4beta,15-epoxy-miller-9E-enolide | Drug Info | [37] | |||
54 | 4beta,15-epoxy-miller-9Z-enolide | Drug Info | [37] | |||
55 | 5-bromo-N-(quinolin-8-yl)thiophene-2-sulfonamide | Drug Info | [38] | |||
56 | 5-chloro-N-(quinolin-8-yl)thiophene-2-sulfonamide | Drug Info | [38] | |||
57 | 5H-6-thia-4,5-diaza-chrysene 6,6-dioxide | Drug Info | [38] | |||
58 | 7-hydroxycostunolide | Drug Info | [37] | |||
59 | 9-chloro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide | Drug Info | [38] | |||
60 | 9-fluoro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide | Drug Info | [38] | |||
61 | 9-methyl-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide | Drug Info | [38] | |||
62 | ACHP | Drug Info | [31] | |||
63 | ARTOBILOXANTHONE | Drug Info | [39] | |||
64 | ARTORIGIDIN A | Drug Info | [39] | |||
65 | ATRIPLICIOLIDTIGLATE | Drug Info | [33] | |||
66 | BAY11-7082 | Drug Info | [31] | |||
67 | BUDLEIN A | Drug Info | [33] | |||
68 | Caffeic acid phenethyl ester | Drug Info | [40] | |||
69 | Centratherin | Drug Info | [37] | |||
70 | ENHYDRIN | Drug Info | [37] | |||
71 | G6976 | Drug Info | [41] | |||
72 | Helenalin-2-methylbutyrate | Drug Info | [37] | |||
73 | HELENALINMETHACRYLATE | Drug Info | [37] | |||
74 | IkappaB-alphaM | Drug Info | [42] | |||
75 | ISOGOIAZENSOLIDE | Drug Info | [33] | |||
76 | Isohelenin | Drug Info | [43] | |||
77 | Miller-9E-enolide | Drug Info | [37] | |||
78 | Miller-9Z-enolide | Drug Info | [37] | |||
79 | MOLEPHANTIN | Drug Info | [33] | |||
80 | MOLEPHANTININ | Drug Info | [33] | |||
81 | Pycnogenol | Drug Info | [44] | |||
82 | Pyrrolidine dithiocarbamate | Drug Info | [45], [46] | |||
83 | ROCAGLAMIDE | Drug Info | [39] | |||
84 | SCANDENOLIDE | Drug Info | [33] | |||
Modulator | [+] 16 Modulator drugs | + | ||||
1 | Laquinimod | Drug Info | [23] | |||
2 | CZEN-002 | Drug Info | [25] | |||
3 | L-ornithine phenylacetate | Drug Info | [26] | |||
4 | Recoflavone | Drug Info | [12] | |||
5 | Vadimezan | Drug Info | [28] | |||
6 | Avrina | Drug Info | [26] | |||
7 | PMID25553724-Compound-WO2011127048 31 | Drug Info | [17] | |||
8 | PMID25553724-Compound-WO2011127048 32 | Drug Info | [17] | |||
9 | PMID25553724-Compound-WO2011127048 33 | Drug Info | [17] | |||
10 | PMID25553724-Compound-WO2011127048 34 | Drug Info | [17] | |||
11 | PMID25553724-Compound-WO2013082253 31 | Drug Info | [17] | |||
12 | PMID25553724-Compound-WO2013082253 32 | Drug Info | [17] | |||
13 | PMID25553724-Compound-WO2013082253 33 | Drug Info | [17] | |||
14 | PMID25553724-Compound-WO2013082253 34 | Drug Info | [17] | |||
15 | P-1 | Drug Info | [30] | |||
16 | SP-650003 | Drug Info | [47] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation | ||||||
Target QSAR Model |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. | |||||
REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4840). | |||||
REF 3 | ClinicalTrials.gov (NCT03917719) An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (GalaxyDMD). U.S. National Institutes of Health. | |||||
REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7639). | |||||
REF 5 | ClinicalTrials.gov (NCT01047319) A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis. U.S. National Institutes of Health. | |||||
REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 7 | ClinicalTrials.gov (NCT02115659) Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). U.S. National Institutes of Health. | |||||
REF 8 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018001) | |||||
REF 10 | ClinicalTrials.gov (NCT01634230) Emergency Use of OCR-002 in Acute Liver Failure. U.S. National Institutes of Health. | |||||
REF 11 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 12 | DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis. Exp Biol Med (Maywood). 2008 Feb;233(2):180-91. | |||||
REF 13 | ClinicalTrials.gov (NCT01057342) Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer. U.S. National Institutes of Health. | |||||
REF 14 | ClinicalTrials.gov (NCT02173301) A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis. U.S. National Institutes of Health. | |||||
REF 15 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018437) | |||||
REF 16 | A water soluble parthenolide analogue suppresses in vivo tumor growth of two tobacco associated cancers, lung and bladder cancer, by targeting NF- B and generating reactive oxygen species. Int J Cancer. 2011 May 15; 128(10): 2481-2494. | |||||
REF 17 | Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. | |||||
REF 18 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006996) | |||||
REF 19 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020925) | |||||
REF 20 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009941) | |||||
REF 21 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009549) | |||||
REF 22 | Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum. American Journal of Respiratory and Critical Care Medicine. 10/1996; 154(3 Pt 1):783-8. | |||||
REF 23 | Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24. | |||||
REF 24 | Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18. | |||||
REF 25 | US patent application no. US20100278784 A1. | |||||
REF 26 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||||
REF 27 | Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15. | |||||
REF 28 | Auckland Cancer Society Research Centre report | |||||
REF 29 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036491) | |||||
REF 30 | Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002291. | |||||
REF 31 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||||
REF 32 | Gliotoxin inhibits neointimal hyperplasia after vascular injury in rats. J Vasc Res. 2009;46(4):278-89. | |||||
REF 33 | Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54. | |||||
REF 34 | NF-kappaB plays a major role during the systemic and local acute inflammatory response following intestinal reperfusion injury. Br J Pharmacol. 2005 May;145(2):246-54. | |||||
REF 35 | Study of influence of additives of tyloxapol on the chromatographic characteristics of the model compounds: the comparative characterization of micellar mobile phases of tyloxapol and Triton X-100. Biomed Chromatogr. 2009 Jul;23(7):700-6. | |||||
REF 36 | Diffusion of an Ionic Drug in Micellar Aqueous Solutions. Langmuir. 2009 Apr 9;25(6):3425-34. | |||||
REF 37 | Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. | |||||
REF 38 | Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35. | |||||
REF 39 | Cytotoxic and NF-kappaB inhibitory constituents of Artocarpus rigida. J Nat Prod. 2010 May 28;73(5):949-55. | |||||
REF 40 | Beneficial effects of caffeic acid phenethyl ester in a rat model of vascular injury. Br J Pharmacol. 2002 Jun;136(3):353-60. | |||||
REF 41 | Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8542-7. | |||||
REF 42 | An IkappaB-alpha mutant inhibits cytokine gene expression and proliferation in human vascular smooth muscle cells. J Surg Res. 2002 Feb;102(2):198-206. | |||||
REF 43 | Protective effects of isohelenin, an inhibitor of nuclear factor kappaB, in endotoxic shock in rats. J Endotoxin Res. 2002;8(2):99-107. | |||||
REF 44 | Inhibition mechanisms of bioflavonoids extracted from the bark of Pinus maritima on the expression of proinflammatory cytokines. Ann N Y Acad Sci. 2001 Apr;928:141-56. | |||||
REF 45 | Simulated ischemia induces renal tubular cell apoptosis through a nuclear factor-kappaB dependent mechanism. J Urol. 2002 Jul;168(1):248-52. | |||||
REF 46 | Role of nuclear factor-kappaB in a rat model of vascular injury. Naunyn Schmiedebergs Arch Pharmacol. 2001 Oct;364(4):343-50. | |||||
REF 47 | Book (Current Pharmaceutical Design) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.